<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590588</url>
  </required_header>
  <id_info>
    <org_study_id>H-34318</org_study_id>
    <nct_id>NCT02590588</nct_id>
  </id_info>
  <brief_title>Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis</brief_title>
  <official_title>Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Mark Sloan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators expect to enroll 15 participants with relapsed or refractory IgM-associated
      AL amyloidosis onto this Phase II clinical trial. Idelalisib will be self-administered orally
      at a dose of 100 mg twice daily (may be increased to 150 mg (one tablet) twice daily after 3
      months at investigator discretion). Participants will be treated until disease progression,
      unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be
      performed every three months until disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes the use of Idelalisib to treat previously treated patients with
      IgM-associated AL Amyloidosis at Boston Medical Center. Boston Medical Center is
      internationally recognized as a leader in amyloidosis research and patient care through the
      activities of the multidisciplinary Amyloid Center at Boston University. The problematic cell
      in most forms of AL amyloidosis shares similarities with multiple myeloma. However, in the
      small subset of AL Amyloidosis patients with an IgM paraprotein, the cells are more typically
      related to lymphoplasmacytic lymphoma or Waldenstrom's macroglobulinemia. Because clonal
      cluster of differentiation antigen 20 (CD20)+ lymphoplasmacytic cells are usually responsible
      for IgM paraproteins, treatment paradigms based on Waldenstrom's macroglobulinemia (WM) may
      be more appropriate than myeloma-based strategies. Idelalisib has been shown to be active and
      well tolerated in patients with relapsed/refractory non-Hodgkin lymphoma including chronic
      lymphocytic lymphoma, and lymphoplasmacytic lymphoma with or without Waldenström's
      macroglobulinemia (WM). The side effect profile of idelalisib merges well with the known
      predisposition to toxicity of amyloidosis patient.

      The investigators expect to enroll 15 participants with IgM-associated AL amyloidosis onto
      this Phase II clinical trial. Idelalisib will be self-administered orally at a dose of 100 mg
      (1 tablet) twice daily (may be escalated to 150 mg (one tablet) twice daily after 3 months at
      investigator discretion). Participants will be treated until disease progression,
      unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be
      performed every three months until disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate hematologic response according to standard criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Response</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients with organ response using standard AL amyloidosis criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Safety and Tolerability of Agent</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate quality of life according to Functional Assessment of Cancer Therapy Lymphoma Subscale (FACT-Lym) assessment tool</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Idelalisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib daily until unacceptable toxicity or disease progression.</description>
    <arm_group_label>Idelalisib</arm_group_label>
    <other_name>GS-1101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1.1 IgM paraprotein identified on serum immunofixation electrophoresis OR light
        chain-restricted CD20+ lymphoplasmacytic population on biopsy of bone marrow or lymph node
        (identified by H&amp;E/immunohistochemistry or flow cytometry) OR positive myeloid
        differentiation primary response gene 88 (MYD88-L265P) OR CXCR4WHIM mutation (CXCR4
        mutation - warts, hypogammaglobulinemia, infections, myelokathexis) on submitted samples

        3.1.2 Biopsy-proven relapsed or refractory AL amyloidosis

        3.1.3 Age ≥ 18 years

        3.1.4 Eastern Cooperative Oncology Group (ECOG) performance status &lt;2 (see Appendix A.)

        3.1.5 Difference between serum free light chains (FLC) of &gt;30 mg/L or quantifiable IgM
        paraprotein &gt;0.5 g/L

        3.1.6 Participants must have normal organ and marrow function as defined below:

          -  Absolute neutrophil count &gt; 1,000/mm3

          -  Platelets &gt; 50,000/mm3

        3.1.7 Ability to understand and the willingness to sign a written informed consent
        document.

        Exclusion Criteria:

        3.2.1 Previous treatment with idelalisib

        3.2.2 Glomerular filtration rate (GFR) &lt;15 ml/min

        3.2.3 Cardiac biomarker Stage III disease as determined by B-type natriuretic peptide (BNP)
        &gt;100 pg/mL and Troponin-I &gt;0.1 ng/mL (Girnius 2014)

        3.2.4 alanine-aminotransferase (ALT)/aspartate aminotransferase (AST) values &gt;2.5x upper
        limit of normal, Bilirubin &gt;1.5 upper limit of normal (ULN)

        3.2.5 Central nervous system (CNS) malignancy or other active malignancy

        3.2.6 Lactating or pregnant women

        3.2.7 Exposure to another investigational drug within 4 weeks prior to start of study
        treatment

        3.2.8 Ongoing alcohol or drug addiction as determined by investigator

        3.2.9 Amyloid-directed therapy within the past 28 days

        3.2.10 History of Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV)
        (assessed by positive Hepatitis B polymerase chain reaction assay (PCR) or Hepatitis B
        Surface Antigen), and/or Hepatitis C Virus (HCV) infection

        3.2.11 t(11,14) translocation identified on bone marrow cytogenetics or by Fluorescence in
        situ hybridization (FISH)

        3.2.12 Known lytic bone lesions

        3.2.13 Positive cytomegaly virus (CMV) Polymerase chain reaction (PCR)

        3.2.14 Previously untreated AL amyloidosis (Newly diagnosed)

        3.2.15 Unwilling or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John &quot;Mark&quot; Sloan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <results_first_submitted>March 30, 2017</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>John Mark Sloan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>IgM-associated AL amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Idelalisib</title>
          <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>'There was only one patient enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Idelalisib</title>
          <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>only patient enrolled</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Unit of measure based on patient identification</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response</title>
        <description>Evaluate hematologic response according to standard criteria</description>
        <time_frame>3 months</time_frame>
        <population>Number of participants with hematologic response is zero. There was only one patient enrolled and he did not remain on study long enough for his first 3 month response evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Idelalisib</title>
            <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>Evaluate hematologic response according to standard criteria</description>
          <population>Number of participants with hematologic response is zero. There was only one patient enrolled and he did not remain on study long enough for his first 3 month response evaluation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Evaluate time to progression</description>
        <time_frame>1 year</time_frame>
        <population>The evaluation of progression-free survival requires that a patient responds, and then progresses. There was only one patient enrolled and he did not remain on study long enough for his first 3 month response evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Idelalisib</title>
            <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Evaluate time to progression</description>
          <population>The evaluation of progression-free survival requires that a patient responds, and then progresses. There was only one patient enrolled and he did not remain on study long enough for his first 3 month response evaluation.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ Response</title>
        <description>Number of patients with organ response using standard AL amyloidosis criteria.</description>
        <time_frame>3 months</time_frame>
        <population>Number of patients with organ response using standard AL amyloidosis criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Idelalisib</title>
            <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Organ Response</title>
          <description>Number of patients with organ response using standard AL amyloidosis criteria.</description>
          <population>Number of patients with organ response using standard AL amyloidosis criteria.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Safety and Tolerability of Agent</title>
        <description>Number of Participants With Treatment-Related Adverse Events as Assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0</description>
        <time_frame>3 months</time_frame>
        <population>There was only one patient enrolled and he did experience treatment-related adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Idelalisib</title>
            <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Safety and Tolerability of Agent</title>
          <description>Number of Participants With Treatment-Related Adverse Events as Assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0</description>
          <population>There was only one patient enrolled and he did experience treatment-related adverse events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Evaluate quality of life according to Functional Assessment of Cancer Therapy Lymphoma Subscale (FACT-Lym) assessment tool</description>
        <time_frame>3 months</time_frame>
        <population>'There was only one patient enrolled and he did not remain on study long enough for his first protocol-specified quality of life assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Idelalisib</title>
            <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Evaluate quality of life according to Functional Assessment of Cancer Therapy Lymphoma Subscale (FACT-Lym) assessment tool</description>
          <population>'There was only one patient enrolled and he did not remain on study long enough for his first protocol-specified quality of life assessment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Idelalisib</title>
          <description>Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
Idelalisib: Idelalisib daily until unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>increased</sub_title>
                <description>alanine-aminotransferase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>swollen eyelids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>diminished appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>discolored urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Sloan MD</name_or_title>
      <organization>Boston Medical Center</organization>
      <phone>617-638-2367</phone>
      <email>mark.sloan@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

